Bunnell
This article was originally published in The Gray Sheet
Executive Summary
Gains FDA permission to resume normal distribution of the Life Pulse high frequency jet ventilator. The firm's activities previously had been limited by FDA to shipments to existing customers of supplies and, in emergency situations, ventilators. The shipment restrictions were part of a September 1992 order/agreement with FDA that required Bunnell to recall and retrofit its existing Life Pulse devices ("The Gray Sheet" Sept. 21, p. 28). Bunnell President and CEO Bert Bunnell said in an April 6 press release that "the effect of the FDA enforcement action has been mixed. We have sustained heavy losses in personnel and sales, but our customer base has remained largely intact".
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.